Vectura Group PLC (VEC) Receives GBX 169.14 Consensus Price Target from Brokerages

Vectura Group PLC (LON:VEC) has received an average rating of “Buy” from the ten ratings firms that are currently covering the firm, reports. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is GBX 165.50 ($2.29).

VEC has been the subject of a number of recent analyst reports. Peel Hunt decreased their price objective on shares of Vectura Group from GBX 160 ($2.21) to GBX 120 ($1.66) and set a “hold” rating for the company in a report on Wednesday, February 14th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Vectura Group in a report on Monday, January 15th. Royal Bank of Canada upgraded shares of Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price objective for the company in a report on Thursday, December 14th. Shore Capital restated a “buy” rating on shares of Vectura Group in a report on Thursday, January 4th. Finally, Numis Securities restated a “buy” rating and issued a GBX 170 ($2.35) price objective on shares of Vectura Group in a report on Thursday, January 4th.

Vectura Group (LON:VEC) opened at GBX 78.95 ($1.09) on Friday. Vectura Group has a 1-year low of GBX 70 ($0.97) and a 1-year high of GBX 166.97 ($2.31).

TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with's FREE daily email newsletter.

Leave a Reply